Slide 1: Corporate Presentation June 2016
Corporate Presentation June 2016
Slide 2: Safe Harbor Statement
Safe Harborstatement Forward-Looking StatementsThis presentation contains certain statements that may be deemed to be “forward looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended.Forward looking statements app
Slide 3: Our Mission: A New Vision for Colorectal Cancer Prevention
OurMission 3 A New Vision for Colorectal Cancer Prevention By removing barriers, changing perceptions, & increasing willingness for screening
Slide 4: About Check-Cap
About Check-Cap 4 Technology Ingestible X-ray scanning capsule Tracking control and data collection unitImage processing and viewing Clinical Trials $ 50mn raised Nasdaq: CHEK Ongoing in IsraelPlan to initiate U.S. pivotal trial in 2018 GE, Fosun Pharma,Pontifax Founded – 2005, Employees – 58 Locate
Slide 5: Colorectal Cancer a major public health problem
Colorectal Cancer a major public health problem 5 137k50k Source: American Cancer Society World Health Organization J Natl Cancer Inst. 2011; 103:1-12 (Mariotto) 134k49k 471k228k 253k139k 113k48k 1.36m694k Annual new cases world-wide -Annual deaths world-wide - Second leading cause of cancer deaths
Slide 6: Colorectal Cancer highly preventable
Colorectal Cancer highly preventable 6 Small Adenomatous Polyp (< 1cm) Cancer Screening can find polyps that can be removed before they turn into cancer Source: Gastro 1997;112:594-692 (Winawer) ACS recommendations for colorectal cancer early detection Photos: WEO Atlas Precancerous phase, readily d
Slide 7: CRC screening tests: cancer prevention and cancer detection
Source: AGA Institute Guidelines for the Early Detection of Colorectal Cancer and Adenomatous Polyps Gastroenterology 2008; 134: 1570-1595 (Levin) ACS recommendations for colorectal cancer early detection CRC screening testscancer prevention and cancer detection 7 Colonoscopy, Sigmoidoscopy,CT Colon
Slide 8: U.S. screening rates and the national goal
U.S screening ratesand the national goal 8 Source: CDC NHIS Survey results MMWR 2015 CA Cancer J Clin 2014;64:104-17 (Seigel) 2000 2010 2013 2018 80% 59% 35% goal Screening rates Significant declines in colorectal cancer incidence have been attributed to screening ages 50-75 58%
Slide 9: Perceptions and Barriers
Perceptions and Barriers screening colonoscopy 9 Bowel Prep Restricted diet Sedation Pre-test fasting Fear of pain and discomfort Feeling of vulnerability Embarrassment A significant majority judged bowel preparation to be the worst part of the process, and the main barrier Patient Education and Cou
Slide 10: Removal of prep may increase screening rates
Removal of prepmay increase screening rates 10 15% 32% 21% 13% 11% 8% 86% of respondents would be much or somewhat more likely to undergo screening if laxative prep were to be removed. Source: Mayo Clinic Proc. 2007;82(6):666-671 (Beebe) Removal of prepmay increase screening rates 10 15% 32% 21% 13%
Slide 11: Check-Cap System
Check-CapSystem Ingestible scanning capsule 1 Capsule Positioning System - Biocompatible patch worn on patient's back for tracking capsule and recording data 2 3D colon imageviewer 3 Imaging Data + Positioning Data Data upload The Check-Cap System is not available for sale or clinical use in any jur
Slide 12: Ultra-low dose X-ray scanning capsule
Ultra-low dose X-ray scanning capsule 12 Patented technology detects photons XRF CMT from Compton Back-scattering and X-Ray Fluorescence As the capsule moves naturally, it scans the inner lining of the colon in a 360 degree arc, scanning only when in motion Patients drink a small amount of contrast
Slide 13: Patients continue their daily routine
Patientscontinue their daily routine 13 As the capsule travels naturally, it transmits scanning and location Data to the Capsule Positioning System, mapping the structures of the internal colon. The capsule is excreted naturally and the patient is notified. Capsule route in colon Capsule Positioning
Slide 14: Physician review of clinical images
Physician reviewof clinical images 14 Image taken during colonoscopy of a 20-30mm polyp
Slide 15: Clinical data generation
Clinical datageneration 15 75 patients 2010 Capsule motility Germany/Israel Israel Israel/EU 1st clinical scanning capsule Source: Gut. 2016 Mar;65(3):371-3 (Gluck)
Slide 16: Case study: polyp in the sigmoid colon
16 Case studypolyp in the sigmoid colon Fillet-typeprocessing Tube-type processing Image taken during screening colonoscopy of a 20mm polyp on a large stem in the sigmoid colon A section of the sigmoid colon where a polyp was located A 3D map of the colon as captured by the system A/P view
Slide 17: Case study: polyp in the ascending colon
17 Case studypolyp in the ascending colon Fillet-typeprocessing Tube-type processing Image taken during colonoscopy of a 4mm sessile polyp on a haustra in the ascending colon A section of the ascending colon where a polyp was located A 3D map of the colon as captured by the system
Slide 18: Compelling market opportunity
Compelling market opportunity 18 $4B annual U. S. market opportunity** Source: * - population between ages 50-84 at average risk, U.S. Census Bureau, Pop. Division, 2014, company estimates ** - For patients screened once every 5 years at average Check-Cap System price of $600 J Clin Gastroenterol 20
Slide 19: Intellectual Property robust portfolio
Intellectual Property robust portfolio 19 Core patents granted in major jurisdictions 20 granted, 3 allowed, and 35 pending worldwide including the U.S. PTO, European Patent Organization, China, Japan, & India covering the core technology: Intra-Lumen Polyp Detection – system and method for an inges
Slide 20: Management
Management 20 Bill Densel CEO 23 years of healthcare industry experience, including CEO of Beacon Endoscopic, CEO of Dune Medical, Cytyc/Hologic, Boston Scientific, Genzyme Biosurgery. Dr. Yoav KimchyFounder & CTO 12 years of executive R&D experience, including Vice President of R&D at V-Target Ltd.
Slide 21: Financial & Corporate summary
Financial & Corporate summary 21 $11.7 million cash as of March 31, 2016 Financial Position • US IPO: February 2015• Traded on the NASDAQ: CHEK• Warrants traded on the NASDAQ: CHEKW• 12.2 million ordinary shares outstanding• Affiliate ownership: 21% Capital Structure
Slide 22: Target milestones
Targetmilestones 22 * Capital and strategic partner dependent Design release and transfer to productionComplete multi-center clinical study Data release from multi-center clinical studyCE Mark submission U.S Pilot Trial initiation H216 H117 01/08 U.S. Pivotal Trial initiation EU Post Market Study in
Slide 23: Investment highlights
Investment highlights clear strategy Leading-edge technology Significant market opportunity clinically demonstrated Proof of concept and polyp detection Extensive expertise within management & advisory Rebusts!P portfolio
Slide 24: A New Vision For Colorectal Cancer Prevention
A New Vision For Colorectal Cancer Prevention